These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 37371025)

  • 1. Genome Editing for Cystic Fibrosis.
    Wang G
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
    Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
    Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction of Airway Stem Cells: Genome Editing Approaches for the Treatment of Cystic Fibrosis.
    King NE; Suzuki S; Barillà C; Hawkins FJ; Randell SH; Reynolds SD; Stripp BR; Davis BR
    Hum Gene Ther; 2020 Sep; 31(17-18):956-972. PubMed ID: 32741223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene and Base Editing as a Therapeutic Option for Cystic Fibrosis-Learning from Other Diseases.
    Mention K; Santos L; Harrison PT
    Genes (Basel); 2019 May; 10(5):. PubMed ID: 31117296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rewriting CFTR to cure cystic fibrosis.
    Maule G; Ensinck M; Bulcaen M; Carlon MS
    Prog Mol Biol Transl Sci; 2021; 182():185-224. PubMed ID: 34175042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Therapy for Cystic Fibrosis: Progress and Challenges of Genome Editing.
    Maule G; Arosio D; Cereseto A
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Molecular Genetics and the long road to treating cystic fibrosis.
    Harris A
    Hum Mol Genet; 2021 Oct; 30(R2):R264-R273. PubMed ID: 34245257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New and emerging targeted therapies for cystic fibrosis.
    Quon BS; Rowe SM
    BMJ; 2016 Mar; 352():i859. PubMed ID: 27030675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond cystic fibrosis transmembrane conductance regulator therapy: a perspective on gene therapy and small molecule treatment for cystic fibrosis.
    Schneider-Futschik EK
    Gene Ther; 2019 Sep; 26(9):354-362. PubMed ID: 31300729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Therapies to Correct the Cystic Fibrosis Basic Defect.
    Bergeron C; Cantin AM
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34201249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-Modulator Therapies: Developing a Therapy for Every Cystic Fibrosis Patient.
    Egan ME
    Clin Chest Med; 2022 Dec; 43(4):717-725. PubMed ID: 36344076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evidence-based treatment of cystic fibrosis].
    Ringshausen FC; Hellmuth T; Dittrich AM
    Internist (Berl); 2020 Dec; 61(12):1212-1229. PubMed ID: 33201261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies.
    Ensinck MM; Carlon MS
    Cells; 2022 Jun; 11(12):. PubMed ID: 35740997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prime editing functionally corrects cystic fibrosis-causing CFTR mutations in human organoids and airway epithelial cells.
    Bulcaen M; Kortleven P; Liu RB; Maule G; Dreano E; Kelly M; Ensinck MM; Thierie S; Smits M; Ciciani M; Hatton A; Chevalier B; Ramalho AS; Casadevall I Solvas X; Debyser Z; Vermeulen F; Gijsbers R; Sermet-Gaudelus I; Cereseto A; Carlon MS
    Cell Rep Med; 2024 May; 5(5):101544. PubMed ID: 38697102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new era of personalized medicine for cystic fibrosis - at last!
    Quon BS; Wilcox PG
    Can Respir J; 2015; 22(5):257-60. PubMed ID: 26083544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A sheep model of cystic fibrosis generated by CRISPR/Cas9 disruption of the CFTR gene.
    Fan Z; Perisse IV; Cotton CU; Regouski M; Meng Q; Domb C; Van Wettere AJ; Wang Z; Harris A; White KL; Polejaeva IA
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.
    Derichs N
    Eur Respir Rev; 2013 Mar; 22(127):58-65. PubMed ID: 23457166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Cas9 and Cas12a CRISPR editing methods to correct the W1282X-CFTR mutation.
    Santos L; Mention K; Cavusoglu-Doran K; Sanz DJ; Bacalhau M; Lopes-Pacheco M; Harrison PT; Farinha CM
    J Cyst Fibros; 2022 Jan; 21(1):181-187. PubMed ID: 34103250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing.
    Maule G; Casini A; Montagna C; Ramalho AS; De Boeck K; Debyser Z; Carlon MS; Petris G; Cereseto A
    Nat Commun; 2019 Aug; 10(1):3556. PubMed ID: 31391465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted replacement of full-length CFTR in human airway stem cells by CRISPR-Cas9 for pan-mutation correction in the endogenous locus.
    Vaidyanathan S; Baik R; Chen L; Bravo DT; Suarez CJ; Abazari SM; Salahudeen AA; Dudek AM; Teran CA; Davis TH; Lee CM; Bao G; Randell SH; Artandi SE; Wine JJ; Kuo CJ; Desai TJ; Nayak JV; Sellers ZM; Porteus MH
    Mol Ther; 2022 Jan; 30(1):223-237. PubMed ID: 33794364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.